Listen

Press releases

Receive e-mail alerts

Interne link ProQR Announces Presentations at ECFS on Eluforsen for F508del Cystic Fibrosis and at CFF Research Conference
juni 04, 2018 om 11:00 AM UTC
Interne link ProQR Appoints Yi-Tao Yu, Ph.D., to Its Scientific Advisory Board
mei 23, 2018 om 11:00 AM UTC
Interne link ProQR Announces Results for the First Quarter of 2018
mei 09, 2018 om 11:00 AM UTC
Interne link ProQR Announces Conference Presentations for Axiomer® RNA Editing Technology and QR-313 for DEB
april 30, 2018 om 11:00 AM UTC
Interne link ProQR Provides Enrollment Update on QR-110 Clinical Trial and Highlights Ophthalmology Presentations at ARVO
april 23, 2018 om 11:00 AM UTC
Interne link ProQR Announces Annual Meeting of Shareholders
april 11, 2018 om 11:00 AM UTC
Interne link ProQR Appoints ADAR Expert Dr. Peter A. Beal to Scientific Advisory Board to Focus on Axiomer® RNA A-to-I Editing Technology
april 10, 2018 om 11:00 AM UTC
Interne link ProQR to Present at Two Upcoming Conferences
april 03, 2018 om 11:00 AM UTC
Interne link ProQR to Present at Upcoming Investor Conference
maart 05, 2018 om 12:00 PM UTC
Interne link ProQR Announces Results for the Fourth Quarter and Full Year 2017 and Provides Business Update
februari 28, 2018 om 12:00 PM UTC
Interne link ProQR Supports Rare Disease Day 2018 and Honors Henri A. Termeer
februari 27, 2018 om 12:00 PM UTC
Interne link Foundation Fighting Blindness will provide up to $7.5 million in funding to develop ProQR’s candidate QR-421a for Usher syndrome type 2A
februari 12, 2018 om 12:00 PM UTC
Interne link ProQR to Present at Upcoming Scientific Meeting and Investor Conference
februari 06, 2018 om 12:00 PM UTC
Interne link ProQR and Galapagos Announce Research Collaboration on Fibrosis Targets Using ProQR’s Axiomer® technology
januari 08, 2018 om 12:00 PM UTC
Interne link ProQR Announces Extraordinary General Meeting of Shareholders
december 27, 2017 om 12:00 PM UTC
Interne link ProQR Receives Orphan Drug Designation from EMA for Drug Candidate QR-313 for Dystrophic Epidermolysis Bullosa
november 29, 2017 om 12:00 PM UTC
Interne link ProQR to Present at the Annual Piper Jaffray Healthcare Conference
november 21, 2017 om 12:00 PM UTC
Interne link ProQR Announces Results for the Third Quarter of 2017
november 20, 2017 om 12:00 PM UTC
Interne link ProQR Prices Approximately $20 Million Underwritten Public Offering and Concurrent Registered Direct Offering of Ordinary Shares
november 14, 2017 om 12:44 PM UTC
Interne link ProQR Announces Proposed Public Offering of Ordinary Shares
november 13, 2017 om 09:01 PM UTC
Interne link ProQR Doses First LCA 10 Patient in Clinical Trial of QR-110, ProQR’s Lead Program for Genetic Blindness
november 13, 2017 om 12:00 PM UTC
Interne link ProQR Appoints Thaddeus Dryja, M.D. to Scientific Advisory Board
november 09, 2017 om 12:00 PM UTC
Interne link ProQR to Present at EuroTIDES Conference
oktober 31, 2017 om 11:00 AM UTC
Interne link ProQR Announces Management Change and Key Promotions
oktober 26, 2017 om 11:00 AM UTC
Interne link ProQR Announces Presentations and Investor & Analyst Event at the North American Cystic Fibrosis Conference
oktober 24, 2017 om 11:00 AM UTC

Press releases

Interne link ProQR Announces Presentations at ECFS on Eluforsen for F508del Cystic Fibrosis and at CFF Research Conference

Interne link ProQR Appoints Yi-Tao Yu, Ph.D., to Its Scientific Advisory Board

Interne link ProQR Announces Results for the First Quarter of 2018

Interne link ProQR Announces Conference Presentations for Axiomer® RNA Editing Technology and QR-313 for DEB

Interne link ProQR Provides Enrollment Update on QR-110 Clinical Trial and Highlights Ophthalmology Presentations at ARVO

Interne link ProQR Announces Annual Meeting of Shareholders

Interne link ProQR Appoints ADAR Expert Dr. Peter A. Beal to Scientific Advisory Board to Focus on Axiomer® RNA A-to-I Editing Technology

Interne link ProQR to Present at Two Upcoming Conferences

Interne link ProQR to Present at Upcoming Investor Conference

Interne link ProQR Announces Results for the Fourth Quarter and Full Year 2017 and Provides Business Update

Interne link ProQR Supports Rare Disease Day 2018 and Honors Henri A. Termeer

Interne link Foundation Fighting Blindness will provide up to $7.5 million in funding to develop ProQR’s candidate QR-421a for Usher syndrome type 2A

Interne link ProQR to Present at Upcoming Scientific Meeting and Investor Conference

Interne link ProQR and Galapagos Announce Research Collaboration on Fibrosis Targets Using ProQR’s Axiomer® technology

Interne link ProQR Announces Extraordinary General Meeting of Shareholders

Interne link ProQR Receives Orphan Drug Designation from EMA for Drug Candidate QR-313 for Dystrophic Epidermolysis Bullosa

Interne link ProQR to Present at the Annual Piper Jaffray Healthcare Conference

Interne link ProQR Announces Results for the Third Quarter of 2017

Interne link ProQR Prices Approximately $20 Million Underwritten Public Offering and Concurrent Registered Direct Offering of Ordinary Shares

Interne link ProQR Announces Proposed Public Offering of Ordinary Shares

Interne link ProQR Doses First LCA 10 Patient in Clinical Trial of QR-110, ProQR’s Lead Program for Genetic Blindness

Interne link ProQR Appoints Thaddeus Dryja, M.D. to Scientific Advisory Board

Interne link ProQR to Present at EuroTIDES Conference

Interne link ProQR Announces Management Change and Key Promotions

Interne link ProQR Announces Presentations and Investor & Analyst Event at the North American Cystic Fibrosis Conference